...Xetra:BAYN) for Xarelto, presented full trial data at ISTH. GamaMabs combo leads to 40% PFS GamaMabs Pharma S.A....
...Tissue factor pathway inhibitor Sandi Wong, Staff Writer GM102, 3c23k Lonsurf, trifluridine/tipiracil (TAS-102) PF-07055480, SB-525 Xarelto, rivaroxaban (BAY 59-7939) Bayer AG GamaMabs Pharma S.A. Janssen Johnson...

...being tested in solid tumors, including an expansion cohort of patients with MSS-CRC. Researchers from GamaMabs Pharma S.A....
...5 biliary tract cancer patients and 2 of 6 CRC patients 2519 LFB S.A. / GamaMabs Pharma S.A....
...CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. GamaMabs Pharma S.A....

...from expansion cohorts in epithelial ovarian and granulosa ovarian cancers are expected early next year. GamaMabs Pharma S.A....
...rights to the product from LFB S.A. (Les Ulis, France). Claire Quang GM102, 3c23k American Society of Clinical Oncology ASCO GamaMabs Pharma S.A. LFB...

...inhibitor of glioblastoma stem cell marker oligodendrocyte transcription factor 2 (OLIG2) Active Preclinical testing ongoing GamaMabs Pharma S.A....

...potential future bellwethers named by VCs included antiviral play Enyo Pharma S.A.S. and immuno-oncology company GamaMabs Pharma S.A....
...Eligo Bioscience S.A.S., Paris, France Enterome Bioscience S.A., Paris, France Enyo Pharma S.A.S., Lyon, France GamaMabs Pharma S.A....
...its CAR T.” BioCentury (2014) Stephen Hansen, Associate Editor Cellectis S.A. DBV Technologies S.A. Eligo Bioscience S.A.S. Enterome Bioscience S.A. Enyo Pharma GamaMabs Pharma S.A. Genfit...

...Ib expansion in 30 patients. GamaMabs has exclusive, worldwide rights to the product from LFB. GamaMabs Pharma S.A....

...undisclosed targets. Companies and Institutions Mentioned GamaMabs Pharma S.A., Toulouse, France LFB S.A., Les Ulis, France Sidebars GamaMabs Pharma S.A....

...throwing their hat in the cancer stem cell ring, providing €3.1 million ($4.2 million) to GamaMabs Pharma S.A....